PLYMOUTH MEETING, Pa., Aug. 4, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that its second quarter 2025 financial results will be released after the market close on August 12, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update.
The live webcast will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts. The webcast will be archived and available for replay for 90 days following the event.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancers, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson, (267) 429-8567, This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$1.81 |
| Daily Change: | 0.05 2.84 |
| Daily Volume: | 945,541 |
| Market Cap: | US$124.350M |
November 10, 2025 November 10, 2025 November 03, 2025 October 21, 2025 August 26, 2025 | |

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load